{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:48:53Z","timestamp":1792201733505,"version":"4.4.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":148,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1002\/rth2.12763","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:14:24Z","timestamp":1661300064000},"page":"e12763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["Hormonal therapies and venous thrombosis: Considerations for prevention and management"],"prefix":"10.1016","volume":"6","author":[{"given":"Corinne","family":"LaVasseur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvi","family":"Neukam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3926-7127","authenticated-orcid":false,"given":"Thomas","family":"Kartika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9981-8990","authenticated-orcid":false,"given":"Bethany","family":"Samuelson Bannow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Shatzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5790-4700","authenticated-orcid":false,"given":"Thomas G.","family":"DeLoughery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1002\/rth2.12763_bb0010","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1046\/j.1538-7836.2003.00264.x","article-title":"Estrogens, progestogens and thrombosis","volume":"1","author":"Rosendaal","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1002\/rth2.12763_bb0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00045391-200603000-00004","article-title":"Prevalence and causes of persistent use of hormone replacement therapy among postmenopausal women: a follow\u2010up study","volume":"13","author":"Ness","year":"2006","journal-title":"Am J Ther"},{"issue":"13","key":"10.1002\/rth2.12763_bb0020","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"10.1002\/rth2.12763_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow\u2010up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/rth2.12763_bb0030","first-page":"488","article-title":"Hormone therapy and thromboembolic disease","volume":"14","author":"Battaglioli","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"10.1002\/rth2.12763_bb0035","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case\u2010control study","volume":"339","author":"van Hylckama","year":"2009","journal-title":"BMJ"},{"key":"10.1002\/rth2.12763_bb0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.thromres.2016.03.025","article-title":"Duration of oral contraceptive use and the risk of venous thromboembolism. A case\u2010control study","volume":"141","author":"Martinelli","year":"2016","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12763_bb0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fneur.2015.00007","article-title":"Hormonal contraceptives and cerebral venous thrombosis risk: a systematic review and meta\u2010analysis","volume":"6","author":"Amoozegar","year":"2015","journal-title":"Front Neurol"},{"issue":"3","key":"10.1002\/rth2.12763_bb0050","article-title":"Combined oral contraceptives: venous thrombosis","author":"de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"3 Suppl","key":"10.1002\/rth2.12763_bb0055","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1016\/S0010-7824(98)00078-X","article-title":"Oral contraceptive estrogen dose considerations","volume":"58","author":"Kaunitz","year":"1998","journal-title":"Contraception"},{"issue":"4","key":"10.1002\/rth2.12763_bb0060","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2016.06.010","article-title":"Impact of estrogen type on cardiovascular safety of combined oral contraceptives","volume":"94","author":"Dinger","year":"2016","journal-title":"Contraception"},{"issue":"7","key":"10.1002\/rth2.12763_bb0065","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1517\/14656561003724713","article-title":"Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest","volume":"11","author":"Jensen","year":"2010","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1002\/rth2.12763_bb0070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.contraception.2020.10.014","article-title":"Ethinyl estradiol vs estradiol valerate in combined oral contraceptives \u2010 effect on glucose tolerance: a randomized, controlled clinical trial","volume":"103","author":"Haverinen","year":"2021","journal-title":"Contraception"},{"issue":"7","key":"10.1002\/rth2.12763_bb0075","doi-asserted-by":"crossref","first-page":"e2483","DOI":"10.1210\/clinem\/dgaa186","article-title":"Estradiol valerate in COC has more favorable inflammatory profile than synthetic ethinyl estradiol: a randomized trial","volume":"105","author":"Kangasniemi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"7305","key":"10.1002\/rth2.12763_bb0080","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/bmj.323.7305.131","article-title":"Third generation oral contraceptives and risk of venous thrombosis: meta\u2010analysis","volume":"323","author":"Kemmeren","year":"2001","journal-title":"BMJ"},{"issue":"8990","key":"10.1002\/rth2.12763_bb0085","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception","volume":"346","year":"1995","journal-title":"Lancet (London, England)"},{"issue":"9045","key":"10.1002\/rth2.12763_bb0090","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(96)07496-X","article-title":"Population\u2010based study of risk of venous thromboembolism associated with various oral contraceptives","volume":"349","author":"Farmer","year":"1997","journal-title":"Lancet (London, England)"},{"issue":"suppl 3","key":"10.1002\/rth2.12763_bb0095","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0049-3848(11)70009-3","article-title":"Epidemiology of the contraceptive pill and venous thromboembolism","volume":"127","author":"Hannaford","year":"2011","journal-title":"Thromb Res"},{"issue":"4","key":"10.1002\/rth2.12763_bb0100","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ogc.2015.07.007","article-title":"Does the progestogen used in combined hormonal contraception affect venous thrombosis risk?","volume":"42","author":"Han","year":"2015","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.1002\/rth2.12763_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2135","article-title":"Use of combined oral contraceptives and risk of venous thromboembolism: nested case\u2010control studies using the QResearch and CPRD databases","volume":"350","author":"Vinogradova","year":"2015","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/rth2.12763_bb0110","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ijgo.12455","article-title":"A systematic review and meta\u2010analysis of venous thrombosis risk among users of combined oral contraception","volume":"141","author":"Dragoman","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"10.1002\/rth2.12763_bb0115","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.contraception.2010.04.004","article-title":"The use of newer progestins for contraception","volume":"82","author":"Sitruk\u2010Ware","year":"2010","journal-title":"Contraception"},{"issue":"3","key":"10.1002\/rth2.12763_bb0120","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/01.AOG.0000279448.62221.a8","article-title":"Risk of thromboembolism in women taking ethinylestradiol\/drospirenone and other oral contraceptives","volume":"110","author":"Seeger","year":"2007","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1002\/rth2.12763_bb0125","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1345\/aph.1M649","article-title":"Risk of venous thromboembolism with drospirenone in combined oral contraceptive products","volume":"44","author":"Sehovic","year":"2010","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1002\/rth2.12763_bb0130","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone\u2010containing oral contraceptive: final results from the European active surveillance study on oral contraceptives based on 142,475 women\u2010years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"issue":"1","key":"10.1002\/rth2.12763_bb0135","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2125.2005.02373.x","article-title":"Deep vein thrombosis and pulmonary embolism reported in the prescription event monitoring study of Yasmin","volume":"60","author":"Pearce","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1002\/rth2.12763_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f5298","article-title":"Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta\u2010analysis","volume":"347","author":"Stegeman","year":"2013","journal-title":"BMJ"},{"key":"10.1002\/rth2.12763_bb0145","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d2519","article-title":"The risk of deep venous thrombosis with oral contraceptives containing drospirenone","volume":"342","author":"Dunn","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/rth2.12763_bb0150","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1210\/jc.2003-031158","article-title":"Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study","volume":"89","author":"Guido","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1002\/rth2.12763_bb0155","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.contraception.2016.04.014","article-title":"Progestin\u2010only contraception and thromboembolism: a systematic review","volume":"94","author":"Tepper","year":"2016","journal-title":"Contraception"},{"key":"10.1002\/rth2.12763_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e4944","article-title":"Assessing the risk of venous thromboembolic events in women taking progestin\u2010only contraception: a meta\u2010analysis","volume":"345","author":"Mantha","year":"2012","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/rth2.12763_bb0165","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3109\/09513590.2016.1161743","article-title":"Drospirenone as estrogen\u2010free pill and hemostasis: coagulatory study results comparing a novel 4\u2009mg formulation in a 24 + 4 cycle with desogestrel 75\u2009\u03bcg per day","volume":"32","author":"Regidor","year":"2016","journal-title":"Gynecol Endocrinol"},{"key":"10.1002\/rth2.12763_bb0170","unstructured":"Trussell J AACeICT, 21st ed, Hatcher RA, Trussell J, Nelson AL, et al (Eds), Ayer Company Publishers, Inc., New York 2018. p. 844. Copyright \u00a9 2018 Contraceptive Technology Communications, Inc."},{"key":"10.1002\/rth2.12763_bb0175","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e2990","article-title":"Venous thrombosis in users of non\u2010oral hormonal contraception: follow\u2010up study, Denmark 2001\u201010","volume":"344","author":"Lidegaard","year":"2012","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/rth2.12763_bb0180","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1210\/jc.2015-2237","article-title":"Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta\u2010analysis","volume":"100","author":"Mohammed","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1002\/rth2.12763_bb0185","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.contraception.2007.03.003","article-title":"Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol","volume":"76","author":"Jick","year":"2007","journal-title":"Contraception"},{"issue":"5","key":"10.1002\/rth2.12763_bb0190","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.contraception.2009.12.009","article-title":"Extended case\u2010control study results on thromboembolic outcomes among transdermal contraceptive users","volume":"81","author":"Dore","year":"2010","journal-title":"Contraception"},{"issue":"3","key":"10.1002\/rth2.12763_bb0195","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.thromres.2008.04.022","article-title":"Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross\u2010over study","volume":"123","author":"Fleischer","year":"2009","journal-title":"Thromb Res"},{"issue":"5","key":"10.1002\/rth2.12763_bb0200","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.contraception.2009.12.016","article-title":"ORTHO EVRA and venous thromboembolism: an update","volume":"81","author":"Jick","year":"2010","journal-title":"Contraception"},{"key":"10.1002\/rth2.12763_bb0205","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case\u2010control studies using the QResearch and CPRD databases","volume":"364","author":"Vinogradova","year":"2019","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/rth2.12763_bb0210","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/j.1538-7836.2012.04919.x","article-title":"Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study","volume":"10","author":"Sweetland","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1002\/rth2.12763_bb0215","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1161\/ATVBAHA.110.211482","article-title":"The risk of deep venous thrombosis associated with injectable depot\u2010medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device","volume":"30","author":"van Hylckama","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1002\/rth2.12763_bb0220","first-page":"539","article-title":"Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilization","volume":"97","author":"Meirik","year":"2001","journal-title":"Obstet Gynecol"},{"issue":"13","key":"10.1002\/rth2.12763_bb0225","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.292.13.1573","article-title":"Estrogen plus progestin and risk of venous thrombosis","volume":"292","author":"Cushman","year":"2004","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/rth2.12763_bb0230","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/rth2.12100","article-title":"Biomarkers, menopausal hormone therapy and risk of venous thrombosis: the Women's Health Initiative","volume":"2","author":"Cushman","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"10.1002\/rth2.12763_bb0235","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamainternmed.2013.11074","article-title":"Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens","volume":"174","author":"Smith","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1002\/rth2.12763_bb0240","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/GME.0000000000001823","article-title":"Comparative venous thromboembolic safety of oral and transdermal postmenopausal hormone therapies among women veterans","volume":"28","author":"Blondon","year":"2021","journal-title":"Menopause"},{"issue":"5","key":"10.1002\/rth2.12763_bb0245","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/MOH.0b013e32833c07bc","article-title":"Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women","volume":"17","author":"Olie","year":"2010","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"10.1002\/rth2.12763_bb0250","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/GME.0000000000000956","article-title":"Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative observational study","volume":"25","author":"Crandall","year":"2018","journal-title":"Menopause (New York, NY)"},{"key":"10.1002\/rth2.12763_bb0255","unstructured":"G. G. How many people are lesbian, gay,bisexual, and transgender. Los Angeles, CA: The Williams Institute; 2011."},{"issue":"9","key":"10.1002\/rth2.12763_bb0260","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1210\/jc.2009-0345","article-title":"Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline","volume":"94","author":"Hembree","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/rth2.12763_bb0265","unstructured":"Standards of care for the health of transsexual, transgender, and gender nonconforming people. World Professional Association for Transgender Health; 2011. 2011."},{"issue":"11","key":"10.1002\/rth2.12763_bb0270","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/jth.14626","article-title":"Transgender patients and the role of the coagulation clinician","volume":"17","author":"Connors","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1002\/rth2.12763_bb0275","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ajh.24593","article-title":"Thrombotic issues in transgender medicine: a review","volume":"92","author":"Shatzel","year":"2017","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1002\/rth2.12763_bb0280","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1111\/j.1743-6109.2012.02876.x","article-title":"Long\u2010term evaluation of cross\u2010sex hormone treatment in transsexual persons","volume":"9","author":"Wierckx","year":"2012","journal-title":"J Sex Med"},{"key":"10.1002\/rth2.12763_bb0285","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1161\/CIRCULATIONAHA.118.038584","article-title":"The occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy: results from a large cohort study","volume":"139","author":"Nota","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/rth2.12763_bb0290","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1530\/EJE-10-1038","article-title":"A long\u2010term follow\u2010up study of mortality in transsexuals receiving treatment with cross\u2010sex hormones","volume":"164","author":"Asscheman","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1002\/rth2.12763_bb0295","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/gerona\/60.11.1451","article-title":"Adverse events associated with testosterone replacement in middle\u2010aged and older men: a meta\u2010analysis of randomized, placebo\u2010controlled trials","volume":"60","author":"Calof","year":"2005","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"5","key":"10.1002\/rth2.12763_bb0300","first-page":"395","article-title":"Secondary polycythemia and the risk of venous thromboembolism","volume":"6","author":"Bhatt","year":"2014","journal-title":"J Clin Med Res"},{"issue":"2","key":"10.1002\/rth2.12763_bb0305","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/smrj.43","article-title":"Erythrocytosis and polycythemia secondary to testosterone replacement therapy in the aging male","volume":"3","author":"Jones","year":"2015","journal-title":"Sex Med Rev"},{"key":"10.1002\/rth2.12763_bb0310","article-title":"Erythrocytosis and thromboembolic events in transgender individuals undergoing masculinizing therapy with testosterone [abstract]","volume":"5","author":"Oakes","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"10.1002\/rth2.12763_bb0315","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1210\/jc.2009-2354","article-title":"Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline","volume":"95","author":"Bhasin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/rth2.12763_bb0320","first-page":"75","article-title":"Extraprostatic complications of testosterone replacement therapy","volume":"28","author":"Volpi","year":"2005","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"10.1002\/rth2.12763_bb0325","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1210\/jc.2009-2575","article-title":"Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta\u2010analysis","volume":"95","author":"Fernandez\u2010Balsells","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1002\/rth2.12763_bb0330","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2217\/WHE.13.31","article-title":"Thrombosis in three postmenopausal women receiving testosterone therapy for low libido","volume":"9","author":"Glueck","year":"2013","journal-title":"Womens Health (Lond Engl)"},{"issue":"3","key":"10.1002\/rth2.12763_bb0335","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/1076029613499819","article-title":"Testosterone therapy, thrombophilia\u2010hypofibrinolysis, and hospitalization for deep venous thrombosis\u2010pulmonary embolus: an exploratory, hypothesis\u2010generating study","volume":"20","author":"Glueck","year":"2014","journal-title":"Clin Appl Thromb Hemost"},{"issue":"8","key":"10.1002\/rth2.12763_bb0340","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.mayocp.2015.05.012","article-title":"Risk of venous thromboembolism in men receiving testosterone therapy","volume":"90","author":"Baillargeon","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1002\/rth2.12763_bb0345","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa1506119","article-title":"Effects of testosterone treatment in older men","volume":"374","author":"Snyder","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12763_bb0350","article-title":"Testosterone treatment and risk of venous thromboembolism: population based case\u2010control study","volume":"355","author":"Martinez","year":"2016","journal-title":"BMJ"},{"issue":"8990","key":"10.1002\/rth2.12763_bb0355","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(95)91926-0","article-title":"Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case\u2010control study. World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception","volume":"346","year":"1995","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1002\/rth2.12763_bb0360","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/jth.12060","article-title":"The risk of venous thrombosis in women over 50\u2009years old using oral contraception or postmenopausal hormone therapy","volume":"11","author":"Roach","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1002\/rth2.12763_bb0365","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2141.2007.06780.x","article-title":"Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations","volume":"139","author":"Pomp","year":"2007","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1002\/rth2.12763_bb0370","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJM200105173442007","article-title":"Oral contraceptives and the risk of venous thrombosis","volume":"344","author":"Vandenbroucke","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1002\/rth2.12763_bb0375","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/bjh.16666","article-title":"The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk","volume":"191","author":"Khialani","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1002\/rth2.12763_bb0380","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/jth.13349","article-title":"Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta\u2010analysis","volume":"14","author":"van Vlijmen","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1002\/rth2.12763_bb0385","doi-asserted-by":"crossref","first-page":"E115","DOI":"10.1503\/cmaj.120677","article-title":"Risk of venous thromboembolism in women with polycystic ovary syndrome: a population\u2010based matched cohort analysis","volume":"185","author":"Bird","year":"2013","journal-title":"CMAJ"},{"issue":"1","key":"10.1002\/rth2.12763_bb0390","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1160\/TH15-01-0045","article-title":"Risk factors for venous thromboembolism in women under combined oral contraceptive. The PILl genetic RIsk monitoring (PILGRIM) study","volume":"115","author":"Suchon","year":"2016","journal-title":"Thromb Haemost"},{"issue":"7","key":"10.1002\/rth2.12763_bb0395","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-11-122945","article-title":"A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor","volume":"111","author":"Gallinaro","year":"2008","journal-title":"Blood"},{"issue":"15","key":"10.1002\/rth2.12763_bb0400","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1182\/blood-2011-05-356071","article-title":"Increased risk of venous thrombosis in persons with clinically diagnosed superficial vein thrombosis: results from the MEGA study","volume":"118","author":"van Langevelde","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1002\/rth2.12763_bb0405","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11239-020-02134-3","article-title":"COVID\u201019 update: COVID\u201019\u2010associated coagulopathy","volume":"50","author":"Becker","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"10.1002\/rth2.12763_bb0410","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/rth2.12439","article-title":"Risk of venous thromboembolism in patients with COVID\u201019: a systematic review and meta\u2010analysis","volume":"4","author":"Nopp","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1002\/rth2.12763_bb0415","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.maturitas.2020.04.019","article-title":"Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID\u201019 pandemic: recommendations from the Spanish Menopause Society, Sociedad Espa\u00f1ola de Ginecolog\u00eda y Obstetricia and Sociedad Espa\u00f1ola de Trombosis y Hemos","volume":"137","author":"Ram\u00edrez","year":"2020","journal-title":"Maturitas"},{"issue":"12","key":"10.1002\/rth2.12763_bb0420","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa121","article-title":"COVID\u201019 and hypercoagulability: potential impact on management with oral contraceptives, estrogen therapy and pregnancy","volume":"161","author":"Spratt","year":"2020","journal-title":"Endocrinology"},{"issue":"3","key":"10.1002\/rth2.12763_bb0425","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/13625187.2020.1766016","article-title":"Contraception during coronavirus\u2010COVID 19 pandemia. Recommendations of the Board of the Italian Society of contraception","volume":"25","author":"Fruzzetti","year":"2020","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1002\/rth2.12763_bb0430","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620938149","article-title":"COVID\u201019: coagulopathy, risk of thrombosis, and the rationale for anticoagulation","volume":"26","author":"Miesbach","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"issue":"9","key":"10.1002\/rth2.12763_bb0435","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa127","article-title":"Estradiol, progesterone, immunomodulation, and COVID\u201019 outcomes","volume":"161","author":"Mauvais\u2010Jarvis","year":"2020","journal-title":"Endocrinology"},{"issue":"8","key":"10.1002\/rth2.12763_bb0440","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.3390\/cancers12082325","article-title":"Sex hormones and hormone therapy during COVID\u201019 pandemic: implications for patients with cancer","volume":"12","author":"Cattrini","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/rth2.12763_bb0445","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/13625187.2021.2000959","article-title":"COVID\u201019, gender and estroprogestins, what do we know?","volume":"27","author":"Fidecicchi","year":"2022","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"9160","key":"10.1002\/rth2.12763_bb0450","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(98)10265-9","article-title":"Thrombosis in pregnancy: maternal and fetal issues","volume":"353","author":"Greer","year":"1999","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1002\/rth2.12763_bb0455","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/ATVBAHA.109.184127","article-title":"Venous thromboembolism in pregnancy","volume":"29","author":"James","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1007","key":"10.1002\/rth2.12763_bb0460","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1136\/pgmj.2009.079822","article-title":"Venous thromboembolic disease and pregnancy","volume":"85","author":"Martineau","year":"2009","journal-title":"Postgrad Med J"},{"key":"10.1002\/rth2.12763_bb0465","unstructured":"Venous thromboembolism and hormonal contraception, Green\u2010Top Guideline [Press Release] 2010."},{"issue":"19","key":"10.1002\/rth2.12763_bb0470","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1001\/jama.293.19.2352","article-title":"Thrombophilia, clinical factors, and recurrent venous thrombotic events","volume":"293","author":"Christiansen","year":"2005","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/rth2.12763_bb0475","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2015-08-665927","article-title":"Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use","volume":"127","author":"Martinelli","year":"2016","journal-title":"Blood"},{"key":"10.1002\/rth2.12763_bb0480","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2017.03.013","article-title":"Oral contraception and menstrual bleeding during treatment of venous thromboembolism: expert opinion versus current practice: combined results of a systematic review, expert panel opinion and an international survey","volume":"153","author":"Klok","year":"2017","journal-title":"Thromb Res"},{"issue":"12","key":"10.1002\/rth2.12763_bb0485","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1345\/aph.1M382","article-title":"Probable drug interaction between warfarin and hormonal contraceptives","volume":"43","author":"Zingone","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1002\/rth2.12763_bb0490","first-page":"961","article-title":"Increased risk of recurrent venous thromboembolism during hormone replacement therapy\u2010\u2010results of the randomized, double\u2010blind, placebo\u2010controlled estrogen in venous thromboembolism trial (EVTET)","volume":"84","author":"Hoibraaten","year":"2000","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1002\/rth2.12763_bb0495","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2710.2010.01202.x","article-title":"Guidelines for the management of chronic medication in the perioperative period: systematic review and formal consensus","volume":"36","author":"Castanheira","year":"2011","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"10.1002\/rth2.12763_bb0500","doi-asserted-by":"crossref","first-page":"e1586","DOI":"10.1210\/clinem\/dgaa966","article-title":"No venous thromboembolism increase among transgender female patients remaining on estrogen for gender\u2010affirming surgery","volume":"106","author":"Kozato","year":"2021","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12763","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rth2.12763","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922023433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922023433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:23:57Z","timestamp":1762863837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922023433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":99,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2475037922023433"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12763","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hormonal therapies and venous thrombosis: Considerations for prevention and management","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis (ISTH)","name":"copyright","label":"Copyright"}],"article-number":"e12763"}}